WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST Has $355.34 Million Position in Edwards Lifesciences Co. (NYSE:EW)

WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its position in Edwards Lifesciences Co. (NYSE:EW) by 6.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,800,000 shares of the medical research company’s stock after purchasing an additional 300,000 shares during the period. Edwards Lifesciences accounts for 4.3% of WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST’s investment portfolio, making the stock its 10th biggest position. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST owned about 0.81% of Edwards Lifesciences worth $355,344,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Nordea Investment Management AB lifted its holdings in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Edwards Lifesciences by 9.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after purchasing an additional 40,348 shares during the period. AIA Group Ltd raised its position in Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after purchasing an additional 358,556 shares during the period. RiverPark Advisors LLC raised its position in Edwards Lifesciences by 58.1% in the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock worth $1,362,000 after purchasing an additional 7,583 shares during the period. Finally, Banque Cantonale Vaudoise raised its position in Edwards Lifesciences by 46.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock worth $5,353,000 after purchasing an additional 25,886 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 1.7 %

Shares of EW stock opened at $72.16 on Monday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The stock’s fifty day moving average price is $71.64 and its 200 day moving average price is $71.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $42.56 billion, a price-to-earnings ratio of 10.41, a price-to-earnings-growth ratio of 3.61 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 EPS. On average, research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on EW. Evercore ISI cut their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Royal Bank of Canada upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, December 5th. The Goldman Sachs Group upped their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Finally, Barclays upped their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $79.40.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,500 shares of company stock worth $2,508,350. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.